IN2014DN07414A - - Google Patents
Info
- Publication number
- IN2014DN07414A IN2014DN07414A IN7414DEN2014A IN2014DN07414A IN 2014DN07414 A IN2014DN07414 A IN 2014DN07414A IN 7414DEN2014 A IN7414DEN2014 A IN 7414DEN2014A IN 2014DN07414 A IN2014DN07414 A IN 2014DN07414A
- Authority
- IN
- India
- Prior art keywords
- domain
- express
- car
- human
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261601910P | 2012-02-22 | 2012-02-22 | |
PCT/US2013/027366 WO2013126733A1 (en) | 2012-02-22 | 2013-02-22 | Use of icos-based cars to enhance antitumor activity and car persistence |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN07414A true IN2014DN07414A (ja) | 2015-04-24 |
Family
ID=49006250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN7414DEN2014 IN2014DN07414A (ja) | 2012-02-22 | 2013-02-22 |
Country Status (14)
Country | Link |
---|---|
US (3) | US9714278B2 (ja) |
EP (3) | EP4230647A1 (ja) |
JP (1) | JP2015509717A (ja) |
KR (1) | KR20140135715A (ja) |
CN (1) | CN104159917A (ja) |
AU (1) | AU2013222288A1 (ja) |
CA (2) | CA3205751A1 (ja) |
EA (1) | EA201491574A1 (ja) |
ES (1) | ES2816450T3 (ja) |
IL (1) | IL233994A0 (ja) |
IN (1) | IN2014DN07414A (ja) |
MX (1) | MX2014010181A (ja) |
SG (1) | SG11201404769UA (ja) |
WO (1) | WO2013126733A1 (ja) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4275699A3 (en) * | 2012-02-22 | 2024-01-03 | The Trustees of the University of Pennsylvania | Use of the cd2 signaling domain in second-generation chimeric antigen receptors |
MX2014010183A (es) | 2012-02-22 | 2015-03-20 | Univ Pennsylvania | Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer. |
CA2869562C (en) | 2012-04-11 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
WO2014099671A1 (en) * | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
DK2958943T3 (da) | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
EP3623380A1 (en) | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
WO2015090230A1 (en) | 2013-12-19 | 2015-06-25 | Novartis Ag | Human mesothelin chimeric antigen receptors and uses thereof |
JP6793902B2 (ja) | 2013-12-20 | 2020-12-02 | ノバルティス アーゲー | 調節可能キメラ抗原受容体 |
EP4303229A3 (en) * | 2014-01-21 | 2024-04-17 | Novartis AG | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
DK3105335T3 (da) * | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
MY191608A (en) | 2014-04-07 | 2022-07-01 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
US10865242B2 (en) * | 2014-04-10 | 2020-12-15 | Seattle Children's Hospital | Method and compositions for cellular immunotherapy |
AR101829A1 (es) | 2014-07-21 | 2017-01-18 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1 |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN106687483B (zh) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | 使用人源化抗-bcma嵌合抗原受体治疗癌症 |
CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
EP3172228B1 (en) * | 2014-07-25 | 2019-02-27 | Theravectys | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule |
JP7084138B2 (ja) | 2014-08-19 | 2022-06-14 | ノバルティス アーゲー | 癌処置に使用するための抗cd123キメラ抗原受容体(car) |
JP7286267B2 (ja) | 2014-08-28 | 2023-06-05 | バイオアトラ インコーポレイテッド | 修飾t細胞に対する条件的活性型キメラ抗原受容体 |
US11111288B2 (en) | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
KR20230149327A (ko) | 2014-09-17 | 2023-10-26 | 노파르티스 아게 | 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화 |
KR20170068504A (ko) | 2014-10-08 | 2017-06-19 | 노파르티스 아게 | 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도 |
EP3240803B1 (en) | 2014-12-29 | 2021-11-24 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
WO2016115482A1 (en) | 2015-01-16 | 2016-07-21 | Novartis Pharma Ag | Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor |
BR112017015453A2 (pt) | 2015-01-26 | 2018-01-23 | Cellectis | células imunes modificadas knockout para receptor de células t, dotadas de receptores quiméricos de antígeno, de ligação a cd123 para o tratamento de linfoma mieloide agudo recorrente/refratário ou neoplasia blástica de células dendríticas plasmacitoides |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
AU2016243124A1 (en) | 2015-03-27 | 2017-11-02 | University Of Southern California | CAR T-cell therapy directed to LHR for the treatment of solid tumors |
JP6843062B2 (ja) * | 2015-03-27 | 2021-03-17 | ユニバーシティ オブ サザン カリフォルニア | Car t細胞免疫療法のための新規標的としてのhla−g |
KR20180012749A (ko) | 2015-04-06 | 2018-02-06 | 지안후아 유 | 교아세포종에 대한 egfr-지시된 car 요법 |
BR112017021500A2 (pt) | 2015-04-08 | 2018-09-25 | Novartis Ag | terapias com cd20, terapias com cd22 e terapias de combinação com uma célula que expressa (car) receptor de antígeno quimérico de cd19 |
EP3283619B1 (en) | 2015-04-17 | 2023-04-05 | Novartis AG | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
CA2984794A1 (en) | 2015-05-07 | 2016-11-10 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
AU2016270474A1 (en) | 2015-06-04 | 2018-01-04 | University Of Southern California | Lym-1 and Lym-2 targeted CAR cell immunotherapy |
EP3325504A1 (en) | 2015-07-21 | 2018-05-30 | Novartis AG | Methods for improving the efficacy and expansion of immune cells |
GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
EP3331920A4 (en) | 2015-08-07 | 2019-04-03 | Seattle Children's Hospital, dba Seattle Children's Research Institute | T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING |
EP3331913A1 (en) | 2015-08-07 | 2018-06-13 | Novartis AG | Treatment of cancer using chimeric cd3 receptor proteins |
EP3342858B1 (en) * | 2015-08-28 | 2023-10-04 | Rohto Pharmaceutical Co., Ltd. | Ror1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ror1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating diseases by using ror1-positive mesenchymal stem cells |
JP6905163B2 (ja) | 2015-09-03 | 2021-07-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | サイトカイン放出症候群を予測するバイオマーカー |
EP3352784A4 (en) | 2015-09-23 | 2019-06-26 | Cytoimmune Therapeutics, LLC | FLT3-FACED CAR CELLS FOR IMMUNOTHERAPY |
CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
WO2017095525A1 (en) | 2015-12-04 | 2017-06-08 | David Scott | Antigen-specific t cells for inducing immune tolerance |
US11547739B2 (en) | 2015-12-16 | 2023-01-10 | La Jolla Institute For Allergy And Immunology | Peptides and methods related to ICOS signaling |
CN109069597A (zh) | 2015-12-22 | 2018-12-21 | 诺华股份有限公司 | 间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗 |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
LT3455261T (lt) | 2016-05-13 | 2022-11-10 | Bioatla, Inc. | Antikūnai prieš ror2, antikūnų fragmentai, jų imunokonjugatai ir panaudojimas |
CN106222200A (zh) * | 2016-07-28 | 2016-12-14 | 深圳爱生再生医学科技有限公司 | 感染混合物及其制备方法 |
CN106047817A (zh) * | 2016-07-28 | 2016-10-26 | 深圳爱生再生医学科技有限公司 | Car‑t细胞及其制备方法与应用 |
CN106191117A (zh) * | 2016-07-28 | 2016-12-07 | 深圳爱生再生医学科技有限公司 | Car表达载体及其构建方法 |
EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
EP3551197B1 (en) | 2016-12-12 | 2023-11-22 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
CN106755397A (zh) * | 2016-12-20 | 2017-05-31 | 江苏省肿瘤医院 | 基因多态性位点的用途和试剂盒 |
WO2018140725A1 (en) | 2017-01-26 | 2018-08-02 | Novartis Ag | Cd28 compositions and methods for chimeric antigen receptor therapy |
CN110612119A (zh) | 2017-02-07 | 2019-12-24 | 西雅图儿童医院(Dba西雅图儿童研究所) | 磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂 |
EP3589295A4 (en) | 2017-02-28 | 2020-11-04 | Endocyte, Inc. | COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY |
US11851659B2 (en) | 2017-03-22 | 2023-12-26 | Novartis Ag | Compositions and methods for immunooncology |
WO2018195339A1 (en) | 2017-04-19 | 2018-10-25 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
EP3645036A1 (en) | 2017-06-30 | 2020-05-06 | Cellectis | Cellular immunotherapy for repetitive administration |
EP3651795A4 (en) * | 2017-07-12 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH AN H3K27M MUTATION |
WO2019030757A1 (en) * | 2017-08-09 | 2019-02-14 | Ctg Pharma Ltd. | CHIMERIC ANTIGEN RECEPTOR FOR HER2 / NEU AND LYMPHOCYTES T THE EXPRESSANT |
RU2020113680A (ru) | 2017-09-19 | 2021-10-20 | Массачусетс Инститьют Оф Текнолоджи | Композиции для т-клеточной терапии с химерным антигенным рецептором и их применения |
WO2019144095A1 (en) | 2018-01-22 | 2019-07-25 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of use for car t cells |
BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
WO2020033273A1 (en) * | 2018-08-04 | 2020-02-13 | AbCyte Therapeutics Inc. | Multi-function and multi-targeting car system and methods for use thereof |
EP3856763A1 (en) | 2018-09-28 | 2021-08-04 | Massachusetts Institute of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
CN116479022A (zh) * | 2018-12-12 | 2023-07-25 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
MX2021009744A (es) | 2019-02-15 | 2021-11-12 | Univ Southern California | Composiciones de anticuerpos lym-1 y lym-2 y constructos car mejorados. |
US11642409B2 (en) | 2019-06-26 | 2023-05-09 | Massachusetts Insttute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2021183675A2 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
EP4118112A1 (en) | 2020-03-10 | 2023-01-18 | Massachusetts Institute of Technology | Compositions and methods for immunotherapy of npm1c-positive cancer |
US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
US20210338833A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
US20240009309A1 (en) * | 2022-07-05 | 2024-01-11 | Neomics Pharmaceuticals Llc | Chimeric antigen receptor comprising bcma nanobody linked to a chimeric intracellular signaling domain |
CN116036299A (zh) * | 2022-08-19 | 2023-05-02 | 天津市中西医结合医院(天津市南开医院) | 间皮素特异性外泌体载体、包含其的载药外泌体、其制备方法及其医药用途 |
EP4342907A1 (en) | 2022-09-21 | 2024-03-27 | AvenCell Europe GmbH | Switchable chimeric antigen receptors and their use |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5763266A (en) | 1989-06-15 | 1998-06-09 | The Regents Of The University Of Michigan | Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells |
DE3923279A1 (de) | 1989-07-14 | 1990-01-18 | Will W Prof Dr Minuth | Minusheets ist ein neues produkt, um zellen in beliebigen behaeltnissen in hochdifferenzierter form auf einer moeglichst natuerlichen unterlage zu kultivieren |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
GB9125768D0 (en) | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5993434A (en) | 1993-04-01 | 1999-11-30 | Genetronics, Inc. | Method of treatment using electroporation mediated delivery of drugs and genes |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6096532A (en) | 1995-06-07 | 2000-08-01 | Aastrom Biosciences, Inc. | Processor apparatus for use in a system for maintaining and growing biological cells |
US5985653A (en) | 1995-06-07 | 1999-11-16 | Aastrom Biosciences, Inc. | Incubator apparatus for use in a system for maintaining and growing biological cells |
US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
US6809184B1 (en) | 1997-12-01 | 2004-10-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies, including FV molecules, and immunoconjugates having high binding affinity for mesothelin and methods for their use |
US6678556B1 (en) | 1998-07-13 | 2004-01-13 | Genetronics, Inc. | Electrical field therapy with reduced histopathological change in muscle |
US7171264B1 (en) | 1999-05-10 | 2007-01-30 | Genetronics, Inc. | Intradermal delivery of active agents by needle-free injection and electroporation |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | GENESIS OF THE RNA INTERFERENCE PATH AS AID OF TARGETED GENTIAN INTERFERENCE |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
ATE373078T1 (de) | 2000-02-24 | 2007-09-15 | Xcyte Therapies Inc | Gleichzeitige stimulation und konzentration von zellen |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
CA2401327C (en) | 2000-03-03 | 2014-05-06 | Valentis, Inc. | Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
WO2001097477A2 (en) | 2000-06-12 | 2001-12-20 | Time Domain Corporation | Method for specifying pulse characteristics |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
US7446190B2 (en) * | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20040014645A1 (en) | 2002-05-28 | 2004-01-22 | Advisys, Inc. | Increased delivery of a nucleic acid construct in vivo by the poly-L-glutamate ("PLG") system |
US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
US20050070841A1 (en) | 2002-07-04 | 2005-03-31 | Inovio As | Electroporation device and injection apparatus |
GB0225279D0 (en) | 2002-10-30 | 2002-12-11 | Celltech R&D Ltd | Biological products |
US20050113564A1 (en) * | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
AU2005250408B2 (en) | 2004-05-27 | 2010-09-23 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
US20070128708A1 (en) | 2005-12-07 | 2007-06-07 | Genetronics, Inc. | Variable volume electroporation chamber and methods therefore |
EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
WO2011097477A1 (en) * | 2010-02-04 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Icos critically regulates the expansion and function of inflammatory human th17 cells |
-
2013
- 2013-02-22 CN CN201380010754.9A patent/CN104159917A/zh active Pending
- 2013-02-22 US US14/376,038 patent/US9714278B2/en active Active
- 2013-02-22 EA EA201491574A patent/EA201491574A1/ru unknown
- 2013-02-22 JP JP2014558877A patent/JP2015509717A/ja not_active Withdrawn
- 2013-02-22 EP EP23161396.9A patent/EP4230647A1/en active Pending
- 2013-02-22 CA CA3205751A patent/CA3205751A1/en active Pending
- 2013-02-22 AU AU2013222288A patent/AU2013222288A1/en not_active Abandoned
- 2013-02-22 CA CA2864688A patent/CA2864688C/en active Active
- 2013-02-22 KR KR1020147024081A patent/KR20140135715A/ko not_active Application Discontinuation
- 2013-02-22 EP EP13751777.7A patent/EP2817330B1/en active Active
- 2013-02-22 IN IN7414DEN2014 patent/IN2014DN07414A/en unknown
- 2013-02-22 SG SG11201404769UA patent/SG11201404769UA/en unknown
- 2013-02-22 EP EP20183978.4A patent/EP3747898B1/en active Active
- 2013-02-22 ES ES13751777T patent/ES2816450T3/es active Active
- 2013-02-22 WO PCT/US2013/027366 patent/WO2013126733A1/en active Application Filing
- 2013-02-22 MX MX2014010181A patent/MX2014010181A/es unknown
-
2014
- 2014-08-07 IL IL233994A patent/IL233994A0/en unknown
-
2017
- 2017-06-29 US US15/637,734 patent/US10577407B2/en active Active
-
2020
- 2020-02-17 US US16/792,771 patent/US11958892B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013126733A1 (en) | 2013-08-29 |
EA201491574A1 (ru) | 2014-12-30 |
KR20140135715A (ko) | 2014-11-26 |
CA2864688C (en) | 2023-09-05 |
US20210009652A1 (en) | 2021-01-14 |
US20170362295A1 (en) | 2017-12-21 |
US10577407B2 (en) | 2020-03-03 |
CN104159917A (zh) | 2014-11-19 |
EP2817330B1 (en) | 2020-07-08 |
EP4230647A1 (en) | 2023-08-23 |
WO2013126733A8 (en) | 2014-09-18 |
JP2015509717A (ja) | 2015-04-02 |
EP2817330A1 (en) | 2014-12-31 |
ES2816450T3 (es) | 2021-04-05 |
IL233994A0 (en) | 2014-09-30 |
CA2864688A1 (en) | 2013-08-29 |
US20150017141A1 (en) | 2015-01-15 |
EP3747898B1 (en) | 2023-03-15 |
US11958892B2 (en) | 2024-04-16 |
SG11201404769UA (en) | 2014-11-27 |
MX2014010181A (es) | 2015-03-20 |
CA3205751A1 (en) | 2013-08-29 |
EP3747898A1 (en) | 2020-12-09 |
AU2013222288A1 (en) | 2014-08-14 |
EP2817330A4 (en) | 2015-12-23 |
US9714278B2 (en) | 2017-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN07414A (ja) | ||
IN2015DN00139A (ja) | ||
IN2014DN06522A (ja) | ||
MX2020005143A (es) | Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer. | |
NZ709059A (en) | Immunotherapy with binding agents | |
PH12015501000A1 (en) | Anti-notch3 antibodies and antibody-drug conjugates | |
IN2014DN11155A (ja) | ||
PH12014501108A1 (en) | Anti-il-36r antibodies | |
MX2015015231A (es) | Métodos y composiciones para mejorar las células t reguladoras de cd4+. | |
MX2015016963A (es) | Metodos y composiciones para reducir la inmunosupresion por celulas de tumor. | |
NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
MX366813B (es) | Polipeptidos de enlace cd3. | |
MX352881B (es) | Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2. | |
MX2014004326A (es) | Anticuerpos a cd1d. | |
IN2015DN04209A (ja) | ||
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
MX2016004420A (es) | Proteinas de union especificas duales dirigidas contra los receptores de células inmunes y autoantígenos de señalización de tlr. | |
UA117567C2 (uk) | Композиція, яка стимулює лактацію, на основі фосфатидилсерину | |
PH12015500903A1 (en) | Anti-prokineticin receptor (prokr) antibodies and uses thereof | |
GB201212586D0 (en) | Cancer treatment | |
MX2015000983A (es) | Composiciones antitranspirantes y metodos. | |
TN2013000246A1 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
TN2014000207A1 (en) | Anti il-36r antibodies | |
AU333838S (en) | Oestrus detector |